Silence Therapeutics plc (SLN) Stock Price & Analysis
Silence Therapeutics plc (SLN) closed at USD 19.71 on Wednesday, October 28, 2026, down 0.35% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 19.78; the Oct 28, 2026 session ranged USD 19.7–19.79 on volume of 2,757,825 shares. Market capitalization is $1.23B, with a 52-week range of USD 4.19–19.87 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:34 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SLN.md
Key facts (SLN)
- Last four reported quarters (through Jun 30, 2026): revenue $615K, net income -$60.0M (-9748.5% margin), free cash flow -$42.3M (SEC filings).
- Analysts: Hold (mean 2.80 on a 1–5 scale) (5 analysts), mean target USD 19.75 (range 19–20).
- Total return with dividends: 1Y +172.6% vs S&P 500 +13.6%; 5Y -10.4% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.09, revenue estimate $21K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SLN)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $21.7M | $31.6M | $43.3M | $559K | $615K |
| Gross profit | $8.2M | $18.8M | $31.4M | $344K | — |
| Operating income | -$61.0M | -$64.4M | -$63.3M | -$91.1M | -$68.3M |
| Net income | -$50.3M | -$54.2M | -$45.3M | -$88.6M | -$60.0M |
| EPS (diluted) | -$0.52 | -$0.49 | -$0.33 | -$0.63 | — |
| Free cash flow | -$57.2M | -$49.5M | -$67.9M | -$62.3M | -$42.3M |
| Gross margin | 37.8% | 59.3% | 72.7% | 61.5% | — |
| Operating margin | -281.9% | -203.5% | -146.4% | -16292.8% | -11106.8% |
| Net margin | -232.4% | -171.4% | -104.7% | -15851.9% | -9748.5% |
| Revenue growth | — | +46.1% | +36.7% | -98.7% | — |
| Cash + short-term investments | — | $68.8M | $147M | $85.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SLN)
P/S 1993.5x · P/B 31.9x · FCF yield -3.45% · Earnings yield -4.89%
Analysts (SLN)
Consensus Hold (mean 2.80 on a 1–5 scale), 5 analysts; mean target USD 19.75 (low 19, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $75 → $20 |
| 2026-08-11 | Morgan Stanley | Target raised | Overweight | $25 → $32 |
Total return (dividends reinvested) (SLN)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +172.6% | -10.4% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +173.6% | -2.2% |
| Volatility (annualized) | 114.6% | 89.8% |
| Max drawdown | -43.8% (Aug 2026→Oct 2026) | -90.0% (Feb 2024→Apr 2025) |
SLN earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 10, 2026 | Quarter ended Jun 30, 2026 | −$0.27 | −$0.11 | Miss −145.5% | +23.2% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.33 | −$0.09 | Miss −266.7% | -5.3% |
| Mar 5, 2026 | Quarter ended Dec 31, 2025 | −$0.27 | −$0.49 | Beat +44.9% | +7.8% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.15 | −$0.21 | Beat +28.6% | +5.4% |
| Aug 7, 2025 | — | — | — | — | -5.3% |
| May 8, 2025 | — | — | — | — | +0.0% |
| Feb 27, 2025 | — | — | — | — | -5.7% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SLN recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 19, 2026 | DEFA14A | Additional proxy material |
| Oct 19, 2026 | DEFA14A | Additional proxy material |
| Oct 19, 2026 | 8-K | Entered a material agreement; Regulation FD disclosure “Transaction Agreement On October 18, 2026, Silence Therapeutics plc, a public limited company incorporated in England and Wales (the " Company "), entered into a transaction agreement (the " Transaction Agreement ") with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (" Purchaser "). The Transaction Agreement provides, among other things, that, subject to the satisfaction or waiver of the conditions set forth therein, Purchaser (or, in the case of the American Depositary Shares of the…” |
| Oct 13, 2026 | Schedule 13G/A | Tetragon Financial Group Limited, Tetragon Financial Management LP: 5.3% of shares, passive 5%+ holder (amended) |
| Oct 13, 2026 | Schedule 13G | Tetragon Financial Group Limited, Tetragon Financial Management LP: 5.2% of shares, passive 5%+ holder |
| Aug 13, 2026 | Schedule 13D/A | Richard Griffiths: 8.0% of shares, 5%+ holder that may seek to influence the company (amended) |
| Aug 13, 2026 | Schedule 13G/A | Invus Public Equities, L.P., Invus Public Equities Advisors, LLC: 7.0% of shares, passive 5%+ holder (amended) |
| Aug 12, 2026 | 8-K | Entered a material agreement; Other material event “On August 11, 2026, Silence Therapeutics plc (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters set forth therein (collectively, the "Underwriters"), to issue and sell 12,962,963 American Depositary Shares (the "ADSs") of the Company, each representing three ordinary shares, nominal value 0.05 per share in the capital of the Company (the "Ordinary Shares"), in an underwritten public…” |
| Aug 10, 2026 | 8-K | Regulation FD disclosure; Other material event “On August 10, 2026, the Company issued a press release announcing positive topline results from the Phase 2 SANRECO trial, a 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran (6 mg/kg) administered subcutaneously every six weeks ("Q6W") or every twelve weeks ("Q12W") met its primary endpoint and secondary endpoints. Based on the Phase 2 results, the Company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of…” |
| Aug 10, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 10, 2026 | 8-K | Quarterly results |
| Jul 16, 2026 | 8-K/A | Director or executive officer change, or pay arrangement “As reported in the Original Form 8-K, effective as of December 14, 2025 (the "Separation Date"), Craig Tooman agreed by mutual consent to end his employment with Silence Therapeutics plc (the "Company"). On July 10, 2026, the Company and Mr. Tooman entered into a separation and release agreement (the "Separation Agreement"). Pursuant to the Separation Agreement, the Company will provide Mr. Tooman with (a) salary continuation for 12 months following the Separation Date for a total of $655,000, (b) a one-time lump…” |
| Jul 8, 2026 | Schedule 13D/A | 5%+ holder that may seek to influence the company (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SLN revenue by product line (quarter ended Sep 30, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Research Collaboration Income | $159,000 | 100.0% | -89.4% |
| Total revenue | $159,000 | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
SLN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Hansoh Pharmaceutical Group Company | “In October 2021, we announced a collaboration agreement with Hansoh, one of the leading biopharmaceutical companies in China, to develop siRNAs for three undisclosed targets leveraging our proprietary mRNAi GOLD platform.” |
Quoted from the company's 10-K filed Mar 5, 2026.
Companies that name SLN in their SEC reports
| Relationship to SLN | Company | Filing | Sentence |
|---|---|---|---|
| partner | AGIOS PHARMACEUTICALS, INC. (AGIO) | 10-K Feb 12, 2026 | “PharmaEssentia Corp and Incyte Corporation are marketing therapies to treat PV, and Protagonist Therapeutics in collaboration with Takeda, Ionis in collaboration with Ono/Deciphera, Italfarmaco S.p.A., DISC, Merck, and Silence Therapeutics are developing therapies to treat PV; and a number of other biotechnology companies have product candidates in clinical development in similar indications as ours.” |
| partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K Feb 12, 2026 | “Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo Biopharmaceutical Co., Ltd., or Argo, Aro Biotherapeutics, Arrowhead Pharmaceuticals, Inc., or Arrowhead, AstraZeneca plc, or AstraZeneca, Dyne Therapeutics, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Novartis, Novo Nordisk A/S, or Novo Nordisk, SanegeneBio, Sarepta Thera…” |
SLN company outlook (results filed Aug 10, 2026)
- “These forward-looking statements include, but are not limited to, statements about: the Company's business strategy and plans, including the Company's clinical development activities and timelines; the potential therapeutic benefits of the Company's product candidates; and the anticipated timing of initial topline and future results from the SANRECO Phase 2 trial.”
Quoted word-for-word from the SEC 8-K results press release.
SLN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.09 | $-0.10 | +$0.01 | $20,830 | 1 |
| Next quarter (ends Dec 2026) | $-0.10 | $-0.09 | −$0.01 | $4,500 | 1 |
| Current fiscal year (ends Dec 2026) | $-0.36 | $-0.40 | +$0.04 | $328,760 | 2 |
| Next fiscal year (ends Dec 2027) | $-0.38 | $-0.39 | +$0.01 | $760,450 | 2 |
SLN options: expected move
Options price a move of about ±1.1% (±$0.22) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 7 reports the stock moved ±7.5% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 5.9% | ±1.1% |
| Jan 15, 2027 | 79 | 5.5% | ±3.0% |
| Apr 16, 2027 | 170 | 2.9% | ±2.7% |
30-day implied volatility 6% vs 243.8% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:34 UTC)
| Price | USD 19.71 |
|---|---|
| Change | ▼ 0.35% (down) |
| Previous Close | USD 19.78 |
| Open | USD 19.76 |
| Day Range | USD 19.7 – 19.79 |
| 52-Week Range | USD 4.19 – 19.87 |
| Volume | 2,757,825 shares |
| Market Cap | $1.23B |
| Exchange | NGM |
Technical Analysis (SLN)
Nexqual's technical model rates SLN "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:34 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 78.69 (overbought) |
| vs SMA50 | Above (USD 13.22) |
| MACD | 2.28 (positive) |
Analyst Ratings (SLN)
Wall Street analysts rate SLN "Hold" based on 5 analysts, with a mean price target of USD 19.75 (range USD 19–20), per Nexqual as of October 29, 2026 at 06:34 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 19.75 |
| High Target | USD 20 |
| Low Target | USD 19 |
| Buy / Hold / Sell | 1 / 4 / 0 |
Earnings (SLN)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $20,830 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.27 vs est -0.11 ▼ miss |
| 2026-03-31 | USD -0.33 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.21 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:34 UTC.
Financials & Fundamentals (SLN)
| Total Revenue | $615,000 |
|---|---|
| Gross Margin | +85.85% |
| Operating Margin | -10475.61% |
| Profit Margin | +0.00% |
| ROE | -90.41% |
| Debt / Equity | 0 |
| Current Ratio | 7.42 |
| Total Cash | $72.05M |
| Total Debt | $112,000 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$42.27M (-6872.5% of revenue) |
Source: Nexqual, October 29, 2026 at 06:34 UTC.
Financial Health Score (SLN)
Nexqual rates Silence Therapeutics plc's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:34 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $72M cash, no debt |
| Cash Flow | Weak — FCF negative: -$42M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -156%, ROA -56.3% (last 4 quarters, SEC) |
Ownership (SLN)
| Insider Ownership | +7.71% |
|---|---|
| Institutional Ownership | +47.74% |
| Shares Outstanding | 62.20M |
| Float | 37.85M |
| Short % of Float | +5.78% |
Source: Nexqual, October 29, 2026 at 06:34 UTC.
Leadership (SLN)
Silence Therapeutics plc is led by Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D, Interim CEO & Chairman of the Board, per Nexqual as of October 29, 2026 at 06:34 UTC.
| Interim CEO & Chairman of the Board | Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D |
|---|---|
| Executive VP, CFO, Secretary & Executive Director | Rhonda L. Hellums |
| Chief Scientific Officer | Marie Wikstrom Lindholm |
Major Backers & Investors (SLN)
Notable institutional backers of Silence Therapeutics plc include Fidelity, Siren, L.L.C., TCG Crossover Management, LLC, according to Nexqual as of October 29, 2026 at 06:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 5.51% |
| Siren, L.L.C. | 5.5% |
| TCG Crossover Management, LLC | 5.04% |
| Redmile Group, LLC | 3.6% |
| Nantahala Capital Management, LLC | 2.24% |
| Citadel | 2.21% |
| Nextech Invest, Ltd. | 1.58% |
| Millennium Management | 1.51% |
Source: Nexqual, October 29, 2026 at 06:34 UTC.
From Silence Therapeutics plc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as "gene silencing." Our proprietary mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform consists of siRNA product candidates designed to precisely target and ‘silence' specific disease-associated genes in the liver.
- We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, including seeking, maintaining, enforcing and defending patent rights and protecting our related know-how for our siRNA platform technologies such as siRNA stabilization chemistries, as well as for our specific siRNA targeting sequences and related therapeutics and processes, whether developed internally or licensed to third parties.
- Our policy is to seek to protect our proprietary position early, generally by filing an initial priority filing in the European Patent Office.
- We have built a promising pipeline of siRNA product candidates based on our mRNAi GOLD platform for rare and common diseases with high unmet need.
Partnerships
- In October 2021, we announced a collaboration agreement with Hansoh, one of the leading biopharmaceutical companies in China, to develop siRNAs for three undisclosed targets leveraging our proprietary mRNAi GOLD platform.
- SLN312 is our siRNA product candidate under our collaboration with AstraZeneca that works by "silencing" ANGPTL3, an important modulator of lipid metabolism.
Legal & Regulatory Risks (Item 1A, quoted)
- We face potential product liability and other claims, and, if successful claims are brought against us, we may incur substantial liability and costs.
- Our employees, consultants and contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.
- Our relationships with U.S. healthcare providers, including physicians, and third-party payers will be subject to applicable U.S. anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:34 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt